Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.

Blood advances - 9 Jun 2020

Estupiñán H Yesid, Bouderlique Thibault, He Chenfei, Berglöf Anna, Gupta Dhanu, Saher Osama, Daza Cruz Miguel Ángel, Peña-Perez Lucia, Yu Liang, Zain Rula, Karlsson Mikael C I, Månsson Robert, Smith C I Edvard

Abstract excerpt

Pharmacological inhibitors of Bruton tyrosine kinase (BTK) have revolutionized treatment of B-lymphocyte malignancies and show great promise for dampening autoimmunity. The predominant BTK inhibitors tether irreversibly by covalently binding to cysteine 481 in the BTK catalytic domain. Substitution of cysteine 481 for serine (C481S) is the most common mechanism for acquired drug resistance. We generated a novel...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to B-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred C57BL

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 32492159
DOI: 10.1182/bloodadvances.2019001319
PMCID: PMC7284087

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effects.PMID 32492159Read ↗

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read ↗

Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.Semantic proximity Read ↗

Battling Btk Mutants With Noncovalent Inhibitors That Overcome Cys481 and Thr474 Mutations.Semantic proximity Read ↗

New Means and Challenges in the Targeting of BTK.Semantic proximity Read ↗

Resistance to Bruton tyrosine kinase inhibitors: the Achilles heel of their success story in lymphoid malignancies.Semantic proximity Read ↗

Resistance to Bruton Tyrosine Kinase Inhibitors.Semantic proximity Read ↗

The role of Bruton’s tyrosine kinase in autoimmunity and implications for therapySemantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogenySemantic proximity Read ↗

From identification of the BTK kinase to effective management of leukemiaSemantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.